06th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160038407 | FLOWABLE COMPOSITION THAT HARDENS ON DELIVERY TO A TARGET TISSUE SITE BENEATH THE SKIN - Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal. In some embodiments, an implantable drug depot for delivering a therapeutic agent is provided, the implantable drug depot comprising (i) a chamber; and (ii) a flowable composition comprising an effective amount of a therapeutic agent disposed within the chamber of the drug depot, the flowable composition capable of hardening when the drug depot is delivered at or near the target tissue site. | 2016-02-11 |
20160038408 | METHODS FOR REDUCING ACUTE AXONAL INJURY - Provided herein are methods for treating an acute axonal injury by intranasally administering to a subject in need thereof an effective amount of a composition that includes a compound having the biological activity of inhibiting the effect of rapid stretch injury on neural stem-cell derived neurons. An example of such a compound is a Ret receptor ligand, such as a GDNF polypeptide. The compound is optionally associated with a delivery reagent. In one embodiment, the method further includes intranasally administering stem cells to the subject, such as neuronal stem cells or adipose-derived stem cells. Also provided herein are methods for decreasing impairment of long term potentiation of hippocampal synapses in a subject after an acute axonal injury. | 2016-02-11 |
20160038409 | Method of Enhancing Delivery of Therapeutic Compounds to the Eye - The invention provides methods for enhancing the delivery of therapeutic compounds to the eye of a subject by administering plasmin or derivatives thereof and the therapeutic compounds to the eye. | 2016-02-11 |
20160038410 | ENCAPSULATION OF PHARMACEUTICALS FOR TASTE MASKING IN CHEWABLE TABLETS - The present disclosure relates to the use of polymers to coat bitter-tasting active pharmaceutical ingredients in a manner that masks the bitter taste of these compounds. Taste masked pharmaceutical formulations in which the particles of pharmaceutically active ingredients are coated with polymers or ion exchange resins are disclosed. The formulations provide taste masked pharmaceutical formulations in which the rapid disintegration of tablets is preserved. A method for preparing such coated particles in a fluidized bed coating process is disclosed. The polymer coating may include a combination of low molecular and high molecular weight water in-soluble polymers, plasticizer and fillers, which provides for a chewable dosage form having a pleasing taste thereby improving patient compliance. | 2016-02-11 |
20160038411 | PULSATILE GASTRIC RETENTIVE DOSAGE FORMS - Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric retentive dosage forms that achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage form. The dosage forms find particular use in administration of acid-labile active agents such as proton pump inhibitors, and in treating gastric acid secretion such as gastro-esophageal reflux disease (GERD) and nocturnal acid breakthrough (NAB). | 2016-02-11 |
20160038412 | SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF - A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube. | 2016-02-11 |
20160038413 | Antimicrobial Amorphous Compositions - The present invention comprises compositions and methods for providing antimicrobial compositions. The antimicrobial compositions comprise gel delivery vehicles comprising stabilized silver, wherein ionic silver is provided to a site for antimicrobial purposes. Methods of making and using such compositions are taught, including application of the silver-containing gel compositions to wounds, burns, abrasions, cuts, surgical incision, sites where skin or organ integrity has been breached, and other sites to supply an antimicrobial environment. | 2016-02-11 |
20160038414 | PARENTERAL DICLOFENAC COMPOSITION - The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-in-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyerlipidemia, and (8) is neither hyperallergenic nor vein irritating. | 2016-02-11 |
20160038415 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE - The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and/or internally. | 2016-02-11 |
20160038416 | DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS - Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes. | 2016-02-11 |
20160038417 | DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS - Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes. | 2016-02-11 |
20160038418 | NANOPARTICLE FABRICATION METHODS, SYSTEMS, AND MATERIALS - Nano-particles are molded in nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The nano-particles can include pharmaceutical compositions, taggants, contrast agents, biologic drugs, drug compositions, organic materials, and the like. The molds can be virtually any shape and less than 10 micron in cross-sectional diameter. | 2016-02-11 |
20160038419 | COMPOSITION AND METHODS FOR THE TREATMENT OF PERIPHERAL NERVE INJURY - Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery. | 2016-02-11 |
20160038420 | NUTRITIONAL AND MEDICINAL ORAL COMPOSITION FOR VETERINARY USE - The invention relates to a method for producing a nutritional and medicinal oral composition for veterinary use, comprising the following steps: a) providing cores of extruded products of complete feed, and b) coating the cores of extruded products of complete feed provided in step a) with at least one layer of a fatty material comprising at least one medicinal agent, said medicinal agent comprising (i) at least one pre-conditioned active substance in the form of a solution or a suspension of said active substance in an oily liquid, or (ii) at least one pre-conditioned active substance in the form of waxy granulates, at a temperature lower than 40° C. | 2016-02-11 |
20160038421 | IMMUNOGENIC COMPOSITION - A process of producing an immunogenic particle includes mixing an aqueous solvent A wherein an antigen(s) is/are dissolved and a water-immiscible organic solvent B wherein an amphiphilic polymer(s) whose hydrophobic segment(s) is/are poly(hydroxy acid) is/are dissolved, to form a reversed-phase emulsion; and removing the solvent from the reversed-phase emulsion to obtain an antigen-adjuvant microparticle complex, wherein the aqueous solvent A and/or the water-immiscible organic solvent B contains a surfactant. | 2016-02-11 |
20160038422 | Tablet Composition for Anti-tuberculosis Antibiotics - Bacterial resistance to antibiotics is increasing worldwide creating a global threat. Tuberculosis (TB), caused by the bacterium | 2016-02-11 |
20160038423 | A PRAMIPEXOLE SUSTAINED RELEASE TABLET FORMULATION AND MANUFACTURING METHOD THEREOF AND USE THEREOF - The present invention relates to a method for preparing the sustained-release tablets via direct compression process, wet granulation process or dry granulation process to obtain the formulations. The present invention also provides a use of the sustained-release tablet formulation of pramipexole in the preparation of pharmaceutical compositions. A sustained release tablet formulation has advantages as follows: breaking out patent monopoly of the innovator preparation, drug dissolution release effects in vitro can be achieved and probably clinical treatment effects can also be accomplished consistent with that of the innovator preparation; abandoning anionic polymers used in the innovator preparation such that making the drug release and absorption not being influenced by the patent body's gastric pH values, in order to avoid the disadvantages of the innovator preparation. Once the tablet formulation is authorized to marketing, the price will be lowered, capable of bringing out effective medical treatment and economical spending for patients. | 2016-02-11 |
20160038424 | Bromocriptine Formulations - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes. | 2016-02-11 |
20160038425 | Non-Gelatin Enteric Soft Capsules - Described herein are pharmaceutical enteric soft capsules that do not contain gelatin as a film-forming polymer. In particular, compositions and methods for manufacturing enteric soft capsules comprising carrageenans as film forming polymers are disclosed. | 2016-02-11 |
20160038426 | EXTENDED-RELEASE TOPIRAMATE CAPSULES - An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s). | 2016-02-11 |
20160038427 | Tamper Resistant Pharmaceutical Formulations - Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material. | 2016-02-11 |
20160038428 | ENCAPSULATION OF HYDROPHOBIC BIOLOGICALLY ACTIVE COMPOUNDS - A composition comprising hydrophobic droplets coated by a shell and dispersed in a matrix and a consumable product comprising the composition are provided. The hydrophobic droplets comprise a hydrophobic compound, the shell comprises an irreversibly denatured protein, and the matrix comprises a protein, a starch, and a polysaccharide. Also provided are methods for preparing the composition and the consumable product. | 2016-02-11 |
20160038429 | Enteric Coated Multiparticulate Composition With Proteinaceous Coating For Improved Storage Stability - A storage stable L-menthol composition includes a tablet, caplet, capsule, or sachet dosage form. The dosage form has (a) a plurality of individual cores containing an L-menthol source and at least one pharmaceutical excipient and (b) a proteinaceous coating of a continuous film of proteinaceous material over the individual cores forming a plurality of proteinaceous coated individual cores. The film is effective to substantially prevent L-menthol in the L-menthol source from leaving the individual cores when stored at a temperature of 40 degrees C. and 75% relative humidity for at least 1 day. The dosage form contains an effective amount of the L-menthol source for treating a gastrointestinal disorder. | 2016-02-11 |
20160038430 | Zoo-Technical Drug Delivery Device - The present invention relates to a veterinary zoo-technical drug delivery system (device) for the simultaneous release of two or more active substances, which system releases the active substances in a substantially constant ratio over a prolonged period of time. The drug delivery system can be in different forms, such as e.g. an implant, or a intravaginal device such as a helical coil, a spring or a ring. | 2016-02-11 |
20160038431 | TIMED, PULSATILE RELEASE SYSTEMS - A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmocokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications. | 2016-02-11 |
20160038432 | ENCAPSULATION OF MESSENGER RNA - The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a mRNA solution and a lipid solution, wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature greater than ambient temperature. | 2016-02-11 |
20160038433 | NANOCAPSULES OF PROTAMINE - The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 μm and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid. | 2016-02-11 |
20160038434 | DEVICE AND METHOD FOR APPLICATION OF A TRANSDERMAL MEMBRANE - A device and method for moving a membrane into contact and out of contact with the surface of a skin of a patient. The membrane contains at least one active pharmaceutical ingredient (API) and is configured to release the API to the patient when the membrane is in contact with the skin. The device includes components which control the timing of the movement of the membrane based on intended drug delivery profiles. The device may control the amount of surface area of the membrane contacting the skin or the pressure of the membrane on the skin to additionally adjust the drug delivery profile. The membrane may be on a translating platform which moves to a down position where the membrane is in contact with the skin or to an up position where the membrane is not in contact with the skin. | 2016-02-11 |
20160038435 | TRANSDERMAL FORMULATIONS OF LAQUINIMOD - This invention provides a transdermal patch comprising a) a backing layer; b) a liner; c) optionally, a highly porous membrane; and d) a pharmaceutical composition comprising: (i) optionally, a pressure sensitive adhesive in an amount of up to about 95 wt % of the pharmaceutical composition, (ii) laquinimod in an amount of about 0.1-20 wt % of the pharmaceutical composition, and (iii) optionally, one or more permeation enhancers in a total amount of up to about 70 wt % of the pharmaceutical composition. This invention also provides a method for delivering laquinimod across the skin of the subject and for treating a human subject afflicted with a form of multiple sclerosis comprising administering to the skin of the subject a transdermal patch as described herein. This invention further provides a transdermal patch as described herein for use in treating a human subject afflicted with a form of multiple sclerosis. | 2016-02-11 |
20160038436 | LUTEIN COMPOSITION SUITABLE FOR INFANT FOOD FORMULATIONS - The present invention is related to a powderous composition which comprises lutein and which is used in infant food formulations or premixes for infant food formulations. | 2016-02-11 |
20160038437 | PROCESSES AND APPARATUS FOR EXTRACTION OF ACTIVE SUBSTANCES AND ENRICHED EXTRACTS FROM NATURAL PRODUCTS - Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described. | 2016-02-11 |
20160038438 | COMBINATION OF NORDIHYDROGUAIARETIC ACID AND AN AMINOGLYCOSIDE - The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections. | 2016-02-11 |
20160038439 | Use of 7-a-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-estra-1,3,5(10)- triene-3,17B-diol and derivatives thereof - The present invention provides the use of a compound of Formula A for the manufacture of a medicament in the treatment of tumor necrosis factor (TNF)-related diseases, and a method for treating a TNF-related disease, said method comprising administering to a subject in need a therapeutically effective amount of a compound of Formula A. | 2016-02-11 |
20160038440 | Astaxanthin Anti-Inflammatory Synergistic Combinations - This invention is directed to compositions having synergistic combinations of astaxanthin with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation. | 2016-02-11 |
20160038441 | METHOD FOR INHIBITING CANCER CELL GROWTH - Disclosed is a method for inhibiting cancer cell growth in a subject in need thereof, comprising administering to the subject an effective amount of a compound from | 2016-02-11 |
20160038442 | MATERIALS AND METHODS FOR CONTROLLING INFECTIONS WITH NEGATIVE PRESSURE WOUND THERAPY - The subject invention provides a method for promoting wound healing and preventing an infection or treating an existing infection with negative pressure wound therapy, said method comprising the steps of providing a sterile disinfectant composition comprising an active agent comprising chlorhexidine and administering the sterile disinfectant composition to the wound site prior to, during and/or following negative pressure wound therapy. The subject invention also provides a kit comprising the sterile disinfectant composition and, optionally, devices for administration of the sterile disinfection composition to the site with negative pressure wound therapy. | 2016-02-11 |
20160038443 | CERAMIDE-LIKE FUNCTION IMPARTING AGENT - Provided are an agent for imparting ceramide-like function, | 2016-02-11 |
20160038444 | MODULATON OF CELLULAR DNA REPAIR ACTIVITY TO INTERCEPT MALIGNANCY - Disclosed herein are methods for identifying compounds that enhance base excision repair, as well as compounds identified thereby and methods of using such compounds in the interception of malignancy, i.e. the prevention of progression of a disease from a state of susceptibility to active disease. Exemplified compounds are acetohexamide and related compounds, as well as benserazide and analogs thereof. Exemplified malignancies are those of human breast cells carrying mutations, in particular, SUM149 cells and HCC1937 cells, which cells carry BRCA1 mutations. | 2016-02-11 |
20160038445 | ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS - The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. | 2016-02-11 |
20160038446 | METHOD FOR IMPEDING SKIN INFLAMMATORY RESPONSE TO AN ENERGY INJURY - A method for treating skin that is subject to an energy injury including the application of concentrated l-lactic acid to the injury area during the inflammatory response of the skin. Reapplication is shown to further reduce the inflammatory symptoms and improve healing time. The concentration of approximately ten percent by weight with around 2.34 pH is proven to be ideal to impede the skin's inflammatory response for sunburn and elevated temperature thermal burns and prevent associated cellular damage compared to untreated sunburns. | 2016-02-11 |
20160038447 | MODULATION OF REGULATORY T CELLS VIA G-COUPLED PROTEIN RECEPTOR 43 - Disclosed herein are compositions and methods that are useful for inducing the development of regulatory T cells (T | 2016-02-11 |
20160038448 | THE INHIBITION OF THE TOXIC EFFECTS OF ISLET AMYLOID FORMATION BY FLURBIPROFEN AND FLURBIPROFEN DERIVATIVES - The subject invention provides a method of reducing the presence of toxic intermediates of amyloidosis from islet amyloid polypeptide (IAPP) in a patient, comprising administering a compound to the patient a compound having the structure: (Formula 1) wherein R1 and R2 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, or R1 and R2 are linked so as to form a cyclopropyl cyclobutyl, cyclopentyl, or cyclohexyl ring; wherein R3, R4, R5, R6 are each independently hydrogen, fluorine or chlorine; and wherein R7 is hydrogen, phenyl, fluorine, chlorine, bromine, hydroxyl, amine, carboxylic acid, C1-C6 alkyl carboxylate, amide, methyl, ethyl, butyl, pentyl, hexyl, or a pharmaceutically acceptable salt or ester thereof, so as to thereby reduce the presence of toxic intermediates of amyloidosis from islet amyloid polypeptide (IAPP) in the patient. | 2016-02-11 |
20160038449 | MULTI-COMPONENT PHARMACEUTICALS FOR TREATING DIABETES - Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat diabetes, and methods for preparing activated fatty acids are provided herein. | 2016-02-11 |
20160038450 | OIL BODY EXTRACTION AND USES - The present invention provides a method of extracting naturally occurring oil bodies comprising obtaining material containing naturally occurring oil bodies, recovering the oil bodies in a wet preparation and drying the oil bodies; and dried oil bodies obtained by the method and uses thereof. | 2016-02-11 |
20160038451 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS - The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect. | 2016-02-11 |
20160038452 | Methods for Administering a Depot of Disulfiram - The present technology generally relates to a method for treating a subject, comprising administering to the subject a composition comprising a depot of disulfiram, wherein the composition is administered to the lumen of the gastrointestinal (GI) tract, the wall of the GI tract or an area that is substantially drained by the hepatic portal circulation or lacteals/lymphatic system. | 2016-02-11 |
20160038453 | METHODS OF TREATING RENAL DISEASE AND OTHER DISORDERS - The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor. | 2016-02-11 |
20160038454 | INTRAVENOUS FORMULATIONS OF TRIPTOLIDE COMPOUNDS AS IMMUNOMODULATORS AND ANTICANCER AGENTS - Intravenous formulations of triptolide and triptolide derivatives are disclosed for use in immunomodulation and anti-proliferative agents. | 2016-02-11 |
20160038455 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF - The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response. | 2016-02-11 |
20160038456 | REGULATION OF CANCER USING NATURAL COMPOUNDS AND/OR DIET - The current invention is directed to a treatment of a proliferative disease comprising administering to a subject in need of such treatment, a composition comprising epigallocatechin-3-gallate (EGCG), curcumin, glucosinolates and, optionally Daikon radish sprout, alone or in combination with providing a ketogenic diet or a modified ketogenic diet to the subject. The invention also provides a composition comprising medium chain triglycerides, epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and its breakdown product sulforaphane, (SFN) (which are found at high levels in broccoli sprouts or sprouts of other cruciferous vegetables), and, optionally Daikon radish sprout. | 2016-02-11 |
20160038457 | METHODS OF MAINTAINING AND IMPROVING MUSCLE FUNCTION - Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition. | 2016-02-11 |
20160038459 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NATAL AND PRE-NATAL CONDITIONS WITH ALPHA-TOCOPHEROL - The present invention provides methods, compositions, and systems for preventing or reducing an allergic condition in an offspring by administering tocopherol to a mother pregnant or nursing the offspring, where the tocopherol in the composition is 98-100% unmodified natural d-alpha tocopherol, and less than 2% gamma tocopherol (e.g., undetectable levels of gamma tocopherol). In certain embodiments, a prenatal tablet or pill is provided composed of such tocopherol compositions in combination with folic acid, iron, and calcium. | 2016-02-11 |
20160038460 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL - The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient. | 2016-02-11 |
20160038461 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF - Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. | 2016-02-11 |
20160038462 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS - The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent. | 2016-02-11 |
20160038463 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment. | 2016-02-11 |
20160038464 | Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan - Neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as celecoxib that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein. | 2016-02-11 |
20160038465 | Compositions and Methods for Non-Surgical Treatment of Ptosis - Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis. | 2016-02-11 |
20160038466 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL - Disclosed herein is a pharmaceutical composition comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain. | 2016-02-11 |
20160038467 | Combination of Immunotherapies with Activators of Tie-2 - The present invention relates to combination therapies comprising at least one activator of Tie-2 and immunotherapies that target immune checkpoints. Combination therapies of the disclosure can provide therapeutic effects not obtained with singly-administered immunotherapies. Combination therapies can be used to increase the therapeutic efficacy of an immunotherapy, to provide lower dosages of an immunotherapy being administered, to lower a toxicity of an immunotherapy, or to manage a side effect of an immunotherapy. | 2016-02-11 |
20160038468 | RIFAXIMIN FOR USE IN THE TREATING OF VAGINAL INFECTIONS - This disclosure relates to rifaximin—for use in the treatment of bacterial vaginal infections. The disclosure also relates to the use of rifaximin for treating infections characterized by the presence of bacteria that may be clindamycin and/or metronidazole resistant. The disclosure also relates to the use of rifaximin to treat patients with vaginal infections who have relapsed following prior treatment or who have bacteria resistant to antibiotics other than rifaximin. | 2016-02-11 |
20160038469 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA - Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed. The methods can include administering the subject an effective amount of 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a derivative thereof, or a pharmaceutically acceptable salt thereof, increase tonic inhibition in neurons of the subject; to increase slow wave sleep (SWS) and/or slow wave activity (SWA), normalize sleep architecture, reduce secondary insomnia, increase non-rapid eye movement (NREM) sleep, increase sleep continuity, enhance delta activity within NREM, increase or improve total sleep time (TST), increase or improve sleep efficiency, reduce total time awake (TAA), reduce number of awakenings (NWA), reduce latency to persistent sleep (LPS), or to reduce wake after sleep onset (WASO), in the subject, or any combination thereof. | 2016-02-11 |
20160038470 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease. | 2016-02-11 |
20160038471 | TREATMENT OF TAUOPATHIES WITH mGluR5 ANTAGONISTS - The treatment of abnormal hyperphosphorylation of tau in brains of patients with metabotropic glutamate receptor 5 (mGluR5) antagonists. The treatment uses the signaling pathway in which the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr | 2016-02-11 |
20160038472 | AGENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF NEOPLASTIC DISEASES - The invention relates to a novel agent in the form of rhodanine derivatives, which has prophylactic, antiproliferative and antimetastatic activity. Said agent can find use in medicine and pharmacology for the prophylaxis and/or treatment of neoplastic diseases of variable localisation. | 2016-02-11 |
20160038473 | ANIMAL TREATMENTS - Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal. | 2016-02-11 |
20160038474 | COMPOSITIONS AND METHODS FOR THE MODULATION OF HEMOGLOBIN (S) - This invention provides pharmaceutical compositions for the aliosteric modulation of hemoglobin (S) and methods for their use in treating disorders mediated by hemoglobin (S) and disorders that would benefit from tissue and/or cellular oxygenation. | 2016-02-11 |
20160038475 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES - Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. | 2016-02-11 |
20160038476 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY - Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, benign prostatic hyperplasia (BPH), Kennedy's disease, androgenetic alopecia, breast cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy. | 2016-02-11 |
20160038477 | ANTIFUNGAL DRUGS - The present invention relates to the administration of compounds of formula (I) for the treatment and/or prevention of fungal infections in subjects in need thereof. The methods of the invention also relates to the administration of pharmaceutical compositions comprising compounds of formula (I) for the treatment and/or prevention of fungal infections in subjects in need thereof. Subjects suffering from fungal infection and immunocompromised subjects may particularly benefit from the methods and compositions of the invention. | 2016-02-11 |
20160038478 | COMPOSITION AND METHODS FOR TREATING SKIN CONDITIONS - Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described. | 2016-02-11 |
20160038479 | Compositions with Thixotropy and Enhanced Dissolution Reproducibility and Stability - The present disclosure provides extended release compositions including, formulations that comprise such compositions, which exhibit desirable dissolution of an active agent while maintaining its physical stability in a dosage form including, for example, providing reduced sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided. | 2016-02-11 |
20160038480 | INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions. | 2016-02-11 |
20160038481 | USE OF BUPRENORPHINE DIMER IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN - The present invention provides method and compositions for the treatment of peripheral neuropathic pain by administering to a patient a therapeutically effective amount of a buprenorphine dimer compound, wherein the two buprenorphine portions are linked via an ethylene spacer, and wherein the spacer is bonded to the two opioid molecules via an ether bond. Preferably, the active agent is provided in the form of an injectable depot. | 2016-02-11 |
20160038482 | VANOXERINE FOR SELF-ADMINISTRATION FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA IN MAMMALS - Methods of administration of vanoxerine wherein a patient, previously and successfully treated for cardiac arrhythmia with vanoxerine is prescribed a further dose for self-administration of a further dose of vanoxerine for treatment of a subsequent occurrence of cardiac arrhythmia. | 2016-02-11 |
20160038483 | HEPATITIS C VIRUS INHIBITORS - The invention provides compounds of formula (I): | 2016-02-11 |
20160038484 | APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME - Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT 6) receptor antagonists are provided for improving the cognition of a Down syndrome patient. Through the use of a mouse model of DS, the Ts65Dn mouse, we disclose evidence herein that 5-HT 6 receptor antagonists may alleviate the cognitive deficits observed in human subjects suffering from DS. Species within the claimed genus of 5-HT6 receptor antagonists restored the cognitive function of Ts65Dn mice almost to the level of control mice as demonstrated by an improved ability to differentiate between a familiar object in a familiar location and a novel object in a novel location. Consequently, the data disclosed herein support the claimed use of 5-HT 6 receptor antagonists for the treatment of cognitive deficits associated with DS. | 2016-02-11 |
20160038485 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS - Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators. | 2016-02-11 |
20160038486 | DRUG FOR RESPIRATORY DISEASES - It is intended to provide a therapeutic agent and/or a preventive agent for a respiratory disease or a therapeutic agent and/or a preventive agent for a sodium channel associated disease. The present invention provides a pharmaceutical comprising a compound represented by the following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: | 2016-02-11 |
20160038487 | NOVEL GLP-1 RECEPTOR MODULATORS - Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ | 2016-02-11 |
20160038488 | Stable and Soluble Formulations of Receptor Tyrosine Kinase Inhibitors, and Methods of Preparation Thereof - The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form. | 2016-02-11 |
20160038489 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING BENZOPYRANYL TETRACYCLES - Disclosed herein is an anti-inflammatory pharmaceutical composition comprising a benzopyranyl tetracycle compound represented by Chemical Formula 1 as an active ingredient. The compound exhibits excellent anti-inflammatory activity by perturbing the post-translational modification of the inflammation mediator HMGB, and thus finds applications in pharmaceutical compositions superior in the treatment or prevention of inflammation-related diseases. | 2016-02-11 |
20160038490 | COMPOSITIONS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES - Methods are provided for treating cancer and other dysproliferative diseases by administering to a subject in need there of a therapeutically effective amount of a synergistic composition comprising an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; wherein said therapeutically effective amount suppresses the growth of dysproliferative cells in vivo. Compositions comprising a combination of an HER2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof; and a CYP26 inhibitor a pharmaceutically acceptable salt or prodrug thereof are also described. | 2016-02-11 |
20160038491 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2016-02-11 |
20160038492 | Targeted Therapies for Cancer - Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer. | 2016-02-11 |
20160038493 | NOVEL CRYSTALLINE FORMS - The present invention relates to novel crystalline polymorphic forms of 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. The present invention also includes the methods of making crystalline polymorphic forms thereof and the use thereof for preparing a pharmaceutical composition. | 2016-02-11 |
20160038494 | NOVEL COMBINATION - The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle). | 2016-02-11 |
20160038495 | BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF - Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. | 2016-02-11 |
20160038496 | NOVEL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR - Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2016-02-11 |
20160038497 | Enhanced Treatment Regimens Using mTOR Inhibitors - The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability. | 2016-02-11 |
20160038498 | METHODS FOR THE TREATMENT OF CANCER - The present invention is directed to methods for treating cancer in a subject, such as a cancer of the endocrine system. In some aspects, the method includes administering to the subject one or more of a polo-like kinase 1 inhibitor, a mouse double minute 2 inhibitor, and/or a mitotic catastrophe inducing compound. In other aspects, the method includes measuring an expression level of one or more markers, including caspase 8 and caspase 9, to assess the functionality of the caspase cascade in the subject. | 2016-02-11 |
20160038499 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 - Compounds and compositions for treating disorders related to TRPA1 are described herein. | 2016-02-11 |
20160038500 | COMBINATION THERAPY - The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor. | 2016-02-11 |
20160038501 | PHARMACEUTICAL COMPOSITIONS COMPRISING BI-1356 AND METFORMIN - The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin. | 2016-02-11 |
20160038502 | HIV TREATMENT FORMULATION OF ATAZANAVIR AND COBICISTAT - Formulations of the HIV compounds atazanavir and cobicistat, and methods of treatment utilizing these formulations, are set forth. | 2016-02-11 |
20160038503 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH ISOQUINOLINE AND QUINOLINE DERIVATIVES - The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. | 2016-02-11 |
20160038504 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent. | 2016-02-11 |
20160038505 | METHODS AND COMPOSITIONS FOR TREATING IMPULSE CONTROL DISORDER, ANXIETY-RELATED DISORDERS, VIOLENCE AND/OR ANGER, OR REGULATING FOOD INTAKE - This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof. | 2016-02-11 |
20160038506 | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof - The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order to achieve an equivalent therapeutic effect. | 2016-02-11 |
20160038507 | Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment - Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: | 2016-02-11 |